Raloxifene - the oral perfect modulator of a receptor of an estrogen (SERM) at which is estrogenic actions on a bone and anti-estrogenic actions on a uterus and a breast. It is used in prevention osteoporosis in concerning the period after менопаузы women. Raloxifene Ilaoj Lille and the Company is made and sold under logo Evista.

On April, 17th 2006, it has been declared that raloxifene it was so effective as  tamoxifene at reduction of level of a cancer of a mammary gland in certain groups of high risk of women, [1] though with the reduced risk thromboembolic events and streams in the patients taking  cheap raloxifene against who take temoxifene on September, 14th 2007, the American Management under the control over products and medicines declared approval raloxifene to reduce risk of an aggressive cancer of a mammary gland in concerning the period after  menopause women with osteoporosis and in concerning the period after menopause women in high risk for an aggressive cancer of a mammary gland.

There was a criticism in the dominating tendency oncology the press of a way by which the information on a preparation has been let out. [3] was some disorder in to put mass-media about value of results of test. There is no certain clinical certificate for use raloxifene in auxiliary treatment of a cancer of a mammary gland, instead of the established drugs, such as tamoxifene or anastrozole.

Tags: Evista, menopausal problems, Raloxifene, tamoxifene

This entry was posted on Пятница, Декабрь 11th, 2009 at 11:52 and is filed under Woman Health. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.